U.S. Food and Drug Administration (FDA) has approved ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution. ZIOPTAN (pronounced zye-OP-tan) is approved for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Open-angle glaucoma is the most common form of glaucoma, while ocular hypertension is a condition characterized by an increase in pressure inside the eye.
ZIOPTAN Rx
Generic Name and Formulations:
Tafluprost 0.0015%; oph soln; preservative-free.
Company:
Akorn, Inc.
Select therapeutic use: Glaucoma
Indications for ZIOPTAN:
For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Adult:
1 drop in conjunctival sac of affected eye(s) once daily in the PM.
Children:
Not recommended.
Warnings/Precautions:
Do not exceed recommended dose (may reduce efficacy). Active intraocular inflammation (eg, iritis/uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Pregnancy (Cat.C); use effective contraception. Nursing mothers.
Interactions:
Allow at least 5 minutes between application of other topical oph agents.
Pharmacological Class:
Prostaglandin analogue.
Adverse Reactions:
Conjunctival hyperemia, ocular stinging/irritation, ocular pruritus including allergic conjunctivitis, cataract, dry eye, ocular pain, increased ocular pigmentation (eg, iris, eyelid, eyelashes; may be permanent), other eyelash changes, blurred vision, macular edema, headache, cold, cough, urinary tract infection.
How Supplied:
Single-use containers (0.3mL)—30, 90 |
